Loading...
Not a good buy right now. TNC is in a bearish technical setup (downtrend across key moving averages with a worsening MACD), options positioning is defensively skewed (heavy put open interest), and the latest quarter (2025/Q3) showed clear YoY deterioration in revenue, earnings, and EPS. With no proprietary buy signals and no near-term news catalyst, an impatient buyer is more likely to face continued churn/downside than a quick rebound—so I would avoid buying here and rate it a sell/avoid for now.
Trend is bearish: SMA_200 > SMA_20 > SMA_5 indicates a sustained downtrend across long-, medium-, and short-term horizons. Momentum is weakening: MACD histogram is -0.353 and negatively expanding, suggesting bearish momentum is accelerating rather than stabilizing. RSI_6 at 41.62 is neutral-to-weak (not oversold), implying there may be room for further downside before a mean-reversion bounce becomes attractive. Key levels: Pivot 77.527 is above the current post-market price (76.09), which keeps price below an important inflection point. Nearest support is S1 at 75.312 (a break below increases risk toward S2 73.943). Resistance levels to reclaim for a bullish shift are 77.527 (pivot) then 79.743 (R1). Pattern-based projection also leans slightly negative over the next month (-1.96%), aligning with the bearish tape.

on 2026-02-23 after hours could act as a catalyst if results or guidance surprise positively.
fundamentals weakened: revenue -3.96% YoY, net income -28.37% YoY, EPS -26.61% YoY—this is not the kind of momentum that typically sparks quick upside. Options positioning is defensively tilted (OI put/call 2.8), suggesting hedging or bearish expectations. No news flow in the last week means no obvious near-term catalyst to reverse sentiment.
Latest quarter: 2025/Q3. Revenue declined to $303.3M (-3.96% YoY). Net income fell to $14.9M (-28.37% YoY). EPS decreased to 0.80 (-26.61% YoY). The main positive was profitability at the gross line: gross margin rose to 42.66% (+0.68% YoY). Overall, the growth trend is negative on top-line and bottom-line, with margin improvement not yet translating into earnings growth—net bearish for a near-term buy decision.
No analyst rating or price target change data was provided, so there is no confirmed recent trend to summarize. With the available information, the closest proxy for 'Wall Street' stance is mixed: institutional/hedge-fund activity appears supportive, but the earnings trajectory and bearish technicals argue against a pro-buy view right now.